Evidence map›Paper›PMID 38238171›Full record

ArticleBMJ open2024

Protocol of the development of a core outcome set for stroke in multidimensional value assessment of traditional Chinese medicine.

Jing Yuan, Lei Yang, Minghui Li, Jingwen Bai, Yinjie Cheng, Yuan Feng, Jing Zhao, Kevin Lu

Open access · goldAbstract read
In one paragraph

Article in BMJ open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Jing Yuan *Minhang Hospital, School of Pharmacy, Fudan University, Shanghai, People's Republic of China jyuan@fudan.edu.cn lu32@email.sc.edu zhao_jing@fudan.edu.cn.ORCID 0000-0003-0906-1822
Lei Yang *Strategic Support Force Medical Center, Beijing, People's Republic of China.
Minghui Li *The University of Tennessee Health Science Center, Memphis, Tennessee, USA.ORCID 0000-0003-1909-6260
Jingwen BaiDepartment of Clinical Pharmacy and Drug Administration, School of Pharmacy, Fudan University, Shanghai, People's Republic of China.
Yinjie ChengDepartment of Clinical Pharmacy and Drug Administration, School of Pharmacy, Fudan University, Shanghai, People's Republic of China.
Yuan FengDepartment of Clinical Pharmacy and Drug Administration, School of Pharmacy, Fudan University, Shanghai, People's Republic of China.
Jing ZhaoDepartment of Neurology, Minhang Hospital, Fudan University, Shanghai, People's Republic of China jyuan@fudan.edu.cn lu32@email.sc.edu zhao_jing@fudan.edu.cn.ORCID 0000-0001-5197-9181
Kevin LuDepartment of Clinical Pharmacy and Outcome Sciences, School of Pharmacy, University of South Carolina, Columbia, South Carolina, USA jyuan@fudan.edu.cn lu32@email.sc.edu zhao_jing@fudan.edu.cn.
Fudan University · CNAir Force General Hospital PLA · CNUniversity of South Carolina · USUniversity of Tennessee Health Science Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionStroke is the most common cause of death in China. In Chinese clinical practise, traditional Chinese medicine (TCM) and integrative medicine have been widely used as adjuvant therapies for the treatment of stroke. However, their clinical effectiveness, particularly their clinical value, has been inconsistent in the literature mainly because various outcome measures have been used and reported in clinical research. Hence, obtaining a comprehensive list of outcomes for TCM value assessment is crucial for a multidimensional value assessment. Therefore, the main objective of this protocol was to develop an outcome set used in health technology assessment (HTA) decision-making for TCM treatment of stroke. METHODS AND ANALYSIS: The outcome set will be developed in four phases: (1) we will perform a systematic literature review to identify candidate outcomes that have been previously measured in published studies; (2) we will develop a comprehensive list of outcome measures by conducting a multistakeholder semistructured interview; (3) we will conduct two-round Delphi surveys to prioritise outcomes for each HTA domain; and (4) we will finalise the outcome sets by holding a ratification meeting with multiple stakeholder groups. The developed outcome set should be measured and reported as the minimum set of outcomes for HTA assessment for the TCM treatment of acute ischaemic stroke (AIS). ETHICS AND DISSEMINATION: This protocol was reviewed and approved by the Institutional Review Board of the Minhang Hospital of Fudan University. Our findings will be shared at academic conferences and in peer-reviewed publications.

Indexed as

Brain IschemiaStrokeDelphi TechniqueHumansMedicine, Chinese TraditionalOutcome Assessment, Health CareResearch DesignSystematic Reviews as TopicTreatment OutcomeDecision MakingHerbal medicineQuality in health careStrokeStroke medicine

Identifiers

PMID38238171
PMCPMC10806626
OpenAlexW4391004369

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.